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feasibility of combined neuroprotection in patients with AIS convincingly are sub-
stantiated by leading Ukrainian neurologists. The aim is to evaluate the economic
feasibility of combined regimens of neuroprotection compared with the
traditional. METHODS: Analysis of the results of comparative clinical trial of three
neuroprotective regimens therapy of patients with moderate and severe AIS: tra-
ditional  citicoline (1 regimen); traditional  citicoline  actovegin (2 regimen); 3
regimen: traditional (pentoxifylline, heparin, acetylsalicylic acid, mannitol) (S. M.
Vinychuk, O. A. Pustova, V.O. Mokchnach et al., 2008) was carried out. Cost-effec-
tiveness analysis was used. Using a decision tree comparing the economic burden
of the three regimens for one year was carried out. RESULTS: The number of pa-
tients who recovered completely after three months were used as efficacy. The
efficacy for 1, 2 and 3 regimens were respectively 29.6%, 38.9% and 23.3%. Direct
costs of the treatment regimens were $ 1.015; $ 1.186; $ 617 for 1, 2 and 3 regimens,
respectively. Incremental cost-effectiveness ratio (ICER) for 1 and 2 regimens were
respectively $6.317, $3.647. The economic burden per one patient for one year were
$ 7006; $ 6511; and $ 6930 for 1, 2 and 3 regimens, respectively. CONCLUSIONS: The
use of regimen 1 and regimen 2 provides greater efficacy and needs greater cost.
With the forecast for one year and taking into account the indirect costs the neu-
roprotective regimen with combination of two drugs (regimen 2) has economic
advantages.
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OBJECTIVES: The prevalence of atrial fibrillation (AF) in France approaches one
million people. The major complication associated with AF is stroke. Current anti-
coagulation options for stroke prevention increase the risk of hemorrhages. Objec-
tives were to estimate the 2-year cumulative incidence and costs of hospitaliza-
tions for strokes and hemorrhages in adults hospitalized for AF and eligible for
stroke prevention. METHODS: Data for patients with an AF-related hospitalization
in 2008 were extracted from the French Hospital National Database (PMSI). Risk
scores (i.e.CHADS2; range:0–6) were calculated from 2006–2008 data. Patient eligi-
ble for stroke prevention with anti-coagulants (i.e.CHADS21) were selected for
the follow-up analysis. Strokes and hemorrhages hospitalizations were identified
according to ICD-10 codes. Strokes severity was based on rehabilitation length and
death. Cumulative incidence was calculated by the number of new hospitalizations
during the 2-year period divided by the number of patients. Mean hospital costs
were calculated from to the 2011 National Hospital Tariff for acute and rehabilita-
tion care. RESULTS: A total of 61,582 AF patients were identified. Mean age was
75.0(11.0) years old and mean CHADS2 was 1.90(0.99). 2-year cumulative inci-
dences of any strokes and hemorrhages were 3.21% (ischemic/60%; hemorrhagic/
24%; unspecified/16%) and 5.31% (gastro-intestinal/26%; intracranial/5%; others/
69%), respectively. Mean costs of ischemic and hemorrhagic strokes were €4,848
and €7,183 (mild), €10,909 and €14,298 (moderate), €29,065 and €29,701 (severe) and,
€6,035 and €4,590 (fatal), respectively. Mean costs of hemorrhages were €3,601 and
€7,331 for gastro-intestinal and intracranial localizations and, €3,941 and €2,552 for
others major and non-major hospitalized bleeds. CONCLUSIONS: Frequencies and
cost of hospitalized hemorrhages appear important to be taking into account in the
global burden of AF. This data should be useful for future French pharmacoeco-
nomic evaluations of new oral anti-coagulants. Thus, this real world data study
may be helpful to assess consistency of patients’ features within recent published
clinical trials.
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OBJECTIVES: To estimate the health care resource utilization and direct costs of
cardioembolic stroke in patients treated in public hospitals of the Region of Madrid
(Spain). METHODS: An observational, prospective study was performed in 5 Neu-
rology services from hospitals in the Region of Madrid, 2 with stroke units (SU) and
3 without stroke units (wSU). Patients with a diagnosis of cardioembolic stroke with
48-hours were recruited in a 4-month period in 2012. Patients’ socio-demo-
graphic, clinical data: disability (modified Rankin scale, mRs), hospital stay and
mortality; complications and health care resource utilization (hospitalisation, in-
patient and at discharge rehabilitation, medication, laboratory tests and specific
therapeutic interventions) were collected. Unitary costs were obtained from na-
tional health care database and the Spanish Catalogue of Medicinal Products (€,
year 2012). RESULTS: Preliminary results from 76 patients (25 SU, 51 wSU) were:
mean age, 74.21.42; 64.5% female; mean mRs at discharge, 2.020.20; non-valvu-
lar atrial fibrilation was the main cause of cardioembolic stroke (28.9%); mean
length of stay, 10.11.14 days; mortality, 5.3%; 42 patients (68.4%) needed in-pa-
tient rehabilitation and 48 patients (63.2%) needed rehabilitation after hospital
discharge; 22 patients (28.9%) suffered hospital complications (63.6% of them suf-
fered infections, 27.3% cardiovascular complications and 59.1% others). Health care
resource utilization differences between SU and wSU hospitals were found in:
length of stay (7.21.26 days, SU; 11.61.55 days, wSU; p-value0.014) and specific
therapeutic interventions (41.7%, SU; 8.0%, wSU; p-value0.001). The overall
4-month cost per patient was 13,647€ (49.2%, hospital stay; 24.8%, rehabilitation at
discharge). CONCLUSIONS: Cardioembolic stroke imposes significant economic
burden for the Public Health System in the Region of Madrid. Key cost drivers were
hospital stay and patients’ rehabilitation at discharge. Patient management in SU
hospitals was associated with more specific therapeutic interventions and shorter
hospital stay than hospitals wSU.
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OBJECTIVES: To evaluate the annual acute and long-term hospitalizations cost of
MR from a French National Payer perspective. METHODS: A 12 months retrospec-
tive population-based study was conducted using the 2009–2010 French Medical
Information System (PMSI). This exhaustive database covers all public and private
hospitals in France and it is based on standardized hospital discharge reports. Each
patient is identified using a unique anonymous identification number allowing a
longitudinal follow-up. Extracted variables included patients’ demographics, out-
comes, acute hospital and post-discharge resource utilizations. RESULTS: 19,868
MR patients were identified and analyzed in two sub-groups depending on their
therapeutic management. In the surgical group (n4,099), the index hospitaliza-
tion length of stay was 17 days, 77% of patients were discharged to a rehabilitation
facility and the average re-hospitalization rate was of 33% over a 6 month period.
The average total cost per patient was €22.152. In the non-surgical group
(n15,769), patients were hospitalized on average 3.1 times over 12 months with an
average length of stay of 7.7 days. Among those patients, 24% were admitted to a
rehabilitation facility (on average 1.5 times) with an average length of stay of 27.9
days. The average total cost per patient was €12.177, varying between €9.957 to
€13.538, without and with heart failure respectively. Detailed analysis showed 2 to
3 times higher costs in the 9th and 10th percentiles. By sub-group, the average cost
of the 10th percentile was €50.268 for the surgical group and €36.503 for the non-
surgical group. CONCLUSIONS: The total observed cost in this population was €283
million over 12 months. Significant differences were observed in cost and resource
used between the surgical and non-surgical groups and depending on type of sur-
gery or presence of heart failure within each subgroup. This is the first study re-
porting hospital costs associated to MR in France.
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OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’
of mortality, morbidity and economic losses. The aim of this study was to estimate
the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS:
For the purpose of the study CVD was defined by the International Classification of
Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis-
ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence,
top-down method was used to quantify the annual cardiovascular costs. Produc-
tivity losses were estimated using the human capital approach and the friction cost
method. Data were collected from Serbian Health Insurance Fund and National
Public Health Institute “Batut”. A discount rate of 5% was used to convert all future
lifetime earnings into the present value. RESULTS: The total direct costs of CVD in
2009 were € 400 million. The majority of total costs (€ 514.3 million) were for:
medication (29.94%), hospital days (28.97%) and hospital inpatient care – surgical
and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac-
counted for 22.15% of total costs. The results showed that more than half a million
working days were lost due to incapacity resulting from CVDs. The results were
robust to a change in20% of volume or the unit price of all direct and indirect cost
and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre-
sented approximately 1.8% of the Serbian gross domestic product. The results of
study would be valuable to health policy makers to bridge the gap between in-
vested resources and needs, in order to improve cardiovascular disease outcomes.
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OBJECTIVES: The risk of cardiovascular risk is higher in patients with diabetes but
what with the cost of this complication? The aim of this study was to compare the
cost of cardiovascular events in patients with and without diabetes in Belgium.
METHODS: Cost of cardiovascular events among hospitalized patients were esti-
mated using the longitudinal IMS Hospital Disease Database (2008), including data
on 34.3% of Belgian hospital beds, combined with Belgian population data. Stays
were identified based on ICD-9 or DRG coding. Cardiac disease included myocardial
infarction (MI; ICD-9:410), angina (ICD-9: 413) and heart failure (ICD-9: 428). Cere-
brovascular disease (CVD) was defined as stroke (APR-DRG:045;046) and Transient
Ischemic Attack (TIA; DRG:047). Diabetes was defined with the ICD-9 codes 249 and
250. Cost comparisons were made using a Wilcoxon non-parametrical test.
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